JP5254207B2 - 抗菌性組成物 - Google Patents
抗菌性組成物 Download PDFInfo
- Publication number
- JP5254207B2 JP5254207B2 JP2009503207A JP2009503207A JP5254207B2 JP 5254207 B2 JP5254207 B2 JP 5254207B2 JP 2009503207 A JP2009503207 A JP 2009503207A JP 2009503207 A JP2009503207 A JP 2009503207A JP 5254207 B2 JP5254207 B2 JP 5254207B2
- Authority
- JP
- Japan
- Prior art keywords
- antibiotics
- composition
- antibiotic
- medical device
- cationic surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 41
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 96
- 230000003115 biocidal effect Effects 0.000 claims abstract description 31
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 27
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 21
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims abstract description 13
- 239000002132 β-lactam antibiotic Substances 0.000 claims abstract description 13
- 229940124586 β-lactam antibiotics Drugs 0.000 claims abstract description 13
- 239000004599 antimicrobial Substances 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 11
- 238000009833 condensation Methods 0.000 claims abstract description 11
- 230000005494 condensation Effects 0.000 claims abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 11
- 239000000194 fatty acid Substances 0.000 claims abstract description 11
- 229930195729 fatty acid Natural products 0.000 claims abstract description 11
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 11
- 229940088710 antibiotic agent Drugs 0.000 claims description 90
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 40
- 229940072056 alginate Drugs 0.000 claims description 39
- 235000010443 alginic acid Nutrition 0.000 claims description 39
- 229920000615 alginic acid Polymers 0.000 claims description 39
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 5
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims description 5
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 4
- 229960001139 cefazolin Drugs 0.000 claims description 4
- 150000001261 hydroxy acids Chemical class 0.000 claims description 4
- 229960003376 levofloxacin Drugs 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 108010093965 Polymyxin B Proteins 0.000 claims description 3
- 229920000024 polymyxin B Polymers 0.000 claims description 3
- 229960005266 polymyxin b Drugs 0.000 claims description 3
- 238000009472 formulation Methods 0.000 abstract description 5
- 150000007660 quinolones Chemical class 0.000 abstract description 4
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 16
- 230000002195 synergetic effect Effects 0.000 description 12
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 11
- 229960003085 meticillin Drugs 0.000 description 11
- 241000191963 Staphylococcus epidermidis Species 0.000 description 7
- 239000000017 hydrogel Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 208000031650 Surgical Wound Infection Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108010049047 Echinocandins Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 3
- 108010015899 Glycopeptides Proteins 0.000 description 3
- 102000002068 Glycopeptides Human genes 0.000 description 3
- 229930189077 Rifamycin Natural products 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001621 bismuth Chemical class 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 229960004023 minocycline Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 3
- 229940081192 rifamycins Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- -1 sutures Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010034396 Streptogramins Proteins 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 229940072174 amphenicols Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003835 ketolide antibiotic agent Substances 0.000 description 2
- 229940041028 lincosamides Drugs 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000001937 non-anti-biotic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002459 polyene antibiotic agent Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229940041030 streptogramins Drugs 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588625 Acinetobacter sp. Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 241000334216 Proteus sp. Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229940123317 Sulfonamide antibiotic Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940116335 lauramide Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
本発明は、(a)脂肪酸とエステル化された二塩基性アミノ酸との縮合によって誘導されたカチオン界面活性剤、および、(b)抗生物質、を含有する新規な抗菌性組成物に関し、更に、それら抗菌性組成物の調製方法および使用方法に関する。より具体的には、本発明は、ラウリンアルギネート(lauric arginate)(LAE)と、β−ラクタム系抗生物質、ポリペプチド系抗生物質およびキノロン系抗生物質から成る群から選ばれた抗生物質とを含有する新規な抗菌性組成物に関する。本発明はまた、そのような新規抗菌性組成物を利用する医療デバイスにも関する。
米国において毎年、患者は、膨大な件数の外科手術を受けている。新しいデータは、1年当り約2700万件の手術が行われていることを示している。術後感染症または手術部位感染症(SSI)は、全ケースの約2〜3%で発生している。これは、毎年675,000を超えるSSI件数に相当する。
本明細書に記述されているのは、抗菌性組成物において、(a)脂肪酸とエステル化された二塩基性アミノ酸との縮合によって誘導されたカチオン界面活性剤[例えば、ラウリンアルギネート(lauric arginate)]と、(b)1種類以上の抗生物質[例えば、β−ラクタム系抗生物質、ポリペプチド系抗生物質、キノロン系(quinolones)抗生物質]とを含有する、抗菌性組成物である。抗菌性組成物は、独立した抗菌性製剤として使用することができるか、または、医療物品もしくは医療デバイスと組み合わせて使用することができる。
本発明は、(a)脂肪酸とエステル化された二塩基性アミノ酸との縮合によって誘導されたカチオン界面活性剤と(b)1種類以上の抗生物質とを含有する抗菌性組成物に向けられている。より具体的には、本発明は、医療デバイスと組み合わせて使用することのできる、ラウリンアルギネートと1種類以上の抗生物質とを含有する抗菌性組成物であって、該医療デバイスの抗菌性が、ラウリンアルギネートと抗生物質とを組み入れることによって改善される、抗菌性組成物に向けられている。そのような組成物は相乗的な抗菌効果を示すことが見出だされた。
Xは、Br、ClまたはHSO4であり、
R1は、アミド結合を通してαアミノ酸基に結合された8〜14個の炭素原子を有する飽和された脂肪酸またはヒドロキシ酸からの直鎖アルキル鎖であり、
R2は、1〜18個の炭素原子からの直鎖アルキル鎖もしくは枝分かれアルキル鎖、または芳香族基であり、
R3は、次のもののうちの1つであり:
nは0〜4とすることができる。
で記述される。
<生体外における(in vitro)抗生物質−ラウリンアルギネート組成物の相乗効果の評価>
ラウリンアルギネートと抗生物質との相乗効果は、表1および表2に示される結果によって説明される。該相乗効果は、次のプロトコールによって決定した。ラウリンアルギネートの滅菌食塩水溶液および抗生物質の滅菌食塩水溶液を、1000ppmの濃度で調製した。次いで、上記2種類の原液から一連の滅菌食塩希釈液を調製した。各々の希釈液の0.05mLの一部を、細菌培養液[106CFU/mLを含有するトリプチカーゼ・ソイ・ブロス(trypticase soy broth)]0.95mLに添加した。対照は、抗生物質もラウリンアルギネートも含有しない複数の試験培養液に同様の量の生理食塩水を含有した。それら試験培養液は37℃で24時間の間培養した。次いで、不活性薬を含有するトリプチカーゼ(Trypticase)(登録商標)ソイ寒天(BBL)の上の平板菌数(plate count)によって、総生菌を数えた。それらの平板は、37℃で48時間の間培養し、次いで、コロニー形成単位/mL(CFU/mL)として記録した。一例として黄色ブドウ球菌(S. aureus)を用い、ラウリンアルギネートも抗生物質も存在させないで、対照培養液を1.1×109CFU/mLに成長させた。
臨床的に意義のある耐性菌であるメチシリン耐性黄色ブドウ球菌(methicillin-resistant Staphylococcus aureus)(MRSA)およびメチシリン耐性表皮ブドウ球菌(methicillin-resistant Staphylococcus epidermidis)(MRSE)に対する、生体外における(in vitro)ラウリンアルギネートと抗生物質との相乗効果は、実施例1に記述されるプロトコールと同一のプロトコールを使用して確認した。表3に結果を示す。使用したMRSEは、MRSE700563およびMRSE51625である。使用したMRSAは、[米国内微生物株保存機関(internal culture collection)からの]MRSA-002およびMRSA-006である。
ラウリンアルギネートおよび抗生物質を含有する組成物の相乗効果は、Nu−Gel(登録商標)ヒドロゲル(英国ガーグレイブ、エチコン社の一部門であるジョンソン・アンド・ジョンソン・メディカル)のような医療デバイスの中に該組成物を組み込んだとき、観察された。ラウリンアルギネートおよび/または抗生物質を含有する複数種類の溶液を、実施例1のようにして調製した。Nu−Gel(登録商標)ヒドロゲルは、0.7×0.7cmの正方形の複数個の断片に切断し、次いで、実施例1および実施例2に記述されるように調製した、ラウリンアルギネートおよび抗生物質の原液の中に10分間浸漬した。処理されたNu−Gel(登録商標)ヒドロゲルの正方形の諸断片は、室温で10分間乾燥させ、次いで、メチシリン耐性黄色ブドウ球菌(methicillin-resistant Staphylococcus aureus)(MRSA)およびメチシリン耐性表皮ブドウ球菌(methicillin-resistant Staphylococcus epidermidis)(MRSE)を接種した複数個のTSA(トリプチカーゼ・ソイ寒天)平板の上に配置した。それらの平板は、37℃で48時間の間培養した。
(1) 抗菌性組成物において、
脂肪酸とエステル化された二塩基性アミノ酸との縮合によって誘導されたカチオン界面活性剤であって、当該カチオン界面活性剤は、次の式に従い:
Xは、Br、ClまたはHSO4であり、
R1は、アミド結合を通してαアミノ酸基に結合された8〜14個の炭素原子を有する飽和された脂肪酸またはヒドロキシ酸からの直鎖アルキル鎖であり、
R2は、1〜18個の炭素原子からの直鎖アルキル鎖もしくは枝分かれアルキル鎖、または芳香族基であり、
R3は、次のもののうちの1つであり:
カチオン界面活性剤と、
少なくとも1種類の抗生物質と、
を含有する、抗菌性組成物。
(2) 実施態様1に記載の抗菌性組成物において、
前記カチオン界面活性剤は、次の式に従うラウリンアルギネート(lauric arginate)である、
(3) 実施態様2に記載の抗菌性組成物において、
前記抗生物質は、ペニシリン系抗生物質、セファロスポリン系(cephalosporins)抗生物質、カルベペネム系(carbepenems)抗生物質、他のβ−ラクタム系抗生物質、アミノグリコシド系(aminoglycosides)抗生物質、アンフェニコール系(amphenicols)抗生物質、アンサマイシン系(ansamycins)抗生物質、マクロライド系(macrolides)抗生物質、リンコサミド系(lincosamides)抗生物質、グリコペプチド系(glycopeptides)抗生物質、ポリペプチド系抗生物質、テトラサイクリン系(tetracylines)抗生物質、クロラムフェニコール(chloramphenicol)、キノロン系(quinolones)抗生物質、フシジン系(fucidins)抗生物質、スルホンアミド系抗生物質、スルホン系抗生物質、ニトロフラン系(nitrofurans)抗生物質、ジアミノピリミジン系抗生物質、トリメトプリム系(trimethoprims)抗生物質、リファマイシン系(rifamycins)抗生物質、オキサリン系(oxalines)抗生物質、ストレプトグラミン系(streptogramins)抗生物質、リポペプチド系(lipopeptides)抗生物質、ケトライド系(ketolides)抗生物質、ポリエン系抗生物質、アゾール系抗生物質、エキノカンジン系(echinocandins)抗生物質、および、それらのあらゆる組合せから成る群から選ばれている、抗菌性組成物。
(4) 実施態様3に記載の抗菌性組成物において、
前記抗生物質は、β−ラクタム系抗生物質、ポリペプチド系抗生物質、キノロン系抗生物質、および、それらのあらゆる組合せから成る群から選ばれている、抗菌性組成物。
(5) 実施態様4に記載の抗菌性組成物において、
前記抗生物質は、セファゾリン(cefazolin)、ポリミキシンB(polymixin B)、レボフロキサシン(levofloxacin)、および、それらのあらゆる組合せである、抗菌性組成物。
(6) 実施態様5に記載の抗菌性組成物において、
前記ラウリンアルギネートの濃度は、前記組成物の全重量に基づき約0.001重量%〜約1重量%の間であり、
前記抗生物質の濃度は、前記組成物の全重量に基づき約0.001重量%〜約1重量%の間である、抗菌性組成物。
(7) 実施態様6に記載の抗菌性組成物において、
前記ラウリンアルギネートおよび前記抗生物質の濃度は、前記組成物の全重量に基づき約0.01重量%〜約0.1重量%の間であり、
抗生物質化合物の濃度は、前記組成物の全重量に基づき約0.01重量%〜約0.1重量%の間である、抗菌性組成物。
(8) 実施態様1〜6のいずれか1項に記載の抗菌性組成物を有する医療デバイス。
Claims (9)
- 抗菌性組成物において、
脂肪酸とエステル化された二塩基性アミノ酸との縮合によって誘導されたカチオン界面活性剤であって、当該カチオン界面活性剤は、次の式に従い:
Xは、Br、ClまたはHSO4であり、
R1は、アミド結合を通してαアミノ酸基に結合された8〜14個の炭素原子を有する飽和された脂肪酸またはヒドロキシ酸からの直鎖アルキル鎖であり、
R2は、1〜18個の炭素原子の直鎖アルキル鎖もしくは枝分かれアルキル鎖、または芳香族基であり、
R3は、次のもののうちの1つであり、
カチオン界面活性剤と、
β−ラクタム系抗生物質、ポリペプチド系抗生物質、キノロン系抗生物質、および、それらのあらゆる組合せから成る群から選ばれている、少なくとも1種類の抗生物質と、
を含有する、抗菌性組成物。 - 請求項1に記載の抗菌性組成物において、
前記抗生物質は、セファゾリン、ポリミキシンB、レボフロキサシン、および、それらのあらゆる組合せである、抗菌性組成物。 - 請求項2に記載の抗菌性組成物において、
前記ラウリンアルギネートの濃度は、前記組成物の全重量に基づき0.001重量%〜1重量%の間であり、
前記抗生物質の濃度は、前記組成物の全重量に基づき0.001重量%〜1重量%の間である、抗菌性組成物。 - 請求項2に記載の抗菌性組成物において、
前記ラウリンアルギネートおよび前記抗生物質の濃度は、前記組成物の全重量に基づき0.01重量%〜0.1重量%の間であり、
抗生物質化合物の濃度は、前記組成物の全重量に基づき0.01重量%〜0.1重量%の間である、抗菌性組成物。 - 抗菌性組成物を有する医療デバイスにおいて、
脂肪酸とエステル化された二塩基性アミノ酸との縮合によって誘導されたカチオン界面活性剤であって、当該カチオン界面活性剤は、次の式に従い:
Xは、Br、ClまたはHSO4であり、
R1は、アミド結合を通してαアミノ酸基に結合された8〜14個の炭素原子を有する飽和された脂肪酸またはヒドロキシ酸からの直鎖アルキル鎖であり、
R2は、1〜18個の炭素原子の直鎖アルキル鎖もしくは枝分かれアルキル鎖、または芳香族基であり、
R3は、次のもののうちの1つであり、
カチオン界面活性剤と、
β−ラクタム系抗生物質、ポリペプチド系抗生物質、キノロン系抗生物質、および、それらのあらゆる組合せから成る群から選ばれている、少なくとも1種類の抗生物質と、
を含有する、医療デバイス。 - 請求項8に記載の医療デバイスにおいて、
前記抗生物質は、セファゾリン、ポリミキシンB、レボフロキサシン、および、それらのあらゆる組合せである、医療デバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/389,824 US8604073B2 (en) | 2006-03-27 | 2006-03-27 | Antimicrobial composition |
US11/389,824 | 2006-03-27 | ||
PCT/US2007/064990 WO2007112379A2 (en) | 2006-03-27 | 2007-03-27 | Antimicrobial composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009531458A JP2009531458A (ja) | 2009-09-03 |
JP5254207B2 true JP5254207B2 (ja) | 2013-08-07 |
Family
ID=38534247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009503207A Expired - Fee Related JP5254207B2 (ja) | 2006-03-27 | 2007-03-27 | 抗菌性組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8604073B2 (ja) |
EP (1) | EP1998615B1 (ja) |
JP (1) | JP5254207B2 (ja) |
CN (1) | CN101573031B (ja) |
AT (1) | ATE478558T1 (ja) |
AU (1) | AU2007230597B2 (ja) |
CA (1) | CA2647642C (ja) |
DE (1) | DE602007008696D1 (ja) |
ES (1) | ES2349065T3 (ja) |
WO (1) | WO2007112379A2 (ja) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9867530B2 (en) | 2006-08-14 | 2018-01-16 | Volcano Corporation | Telescopic side port catheter device with imaging system and method for accessing side branch occlusions |
US9596993B2 (en) | 2007-07-12 | 2017-03-21 | Volcano Corporation | Automatic calibration systems and methods of use |
US10219780B2 (en) | 2007-07-12 | 2019-03-05 | Volcano Corporation | OCT-IVUS catheter for concurrent luminal imaging |
WO2009009799A1 (en) | 2007-07-12 | 2009-01-15 | Volcano Corporation | Catheter for in vivo imaging |
US20100305055A1 (en) | 2007-09-13 | 2010-12-02 | Laboratorios Miret, S.A. | Combinations of polyene fungicide with cationic surfactants |
US20100151104A1 (en) * | 2008-10-27 | 2010-06-17 | Pepsico, Inc. | Preservative System For Beverages Based On Combinations Of Trans-Cinnamic Acid, Lauric Arginate, And Dimethyl Dicarbonate |
US8808724B2 (en) * | 2009-10-28 | 2014-08-19 | Ethicon, Inc. | Antimicrobial coatings with preferred microstructure for medical devices |
WO2012013577A1 (en) * | 2010-07-26 | 2012-02-02 | Laboratorios Miret, S.A. | Composition for coating medical devices containing lae and a polycationic amphoteric polymer |
WO2012051204A2 (en) * | 2010-10-11 | 2012-04-19 | Purdue Research Foundation | Antimicrobial formulations that aid in wound healing |
JP2013520584A (ja) * | 2010-10-14 | 2013-06-06 | ゼウス インダストリアル プロダクツ インコーポレイテッド | 抗菌基質 |
US11141063B2 (en) | 2010-12-23 | 2021-10-12 | Philips Image Guided Therapy Corporation | Integrated system architectures and methods of use |
US11040140B2 (en) | 2010-12-31 | 2021-06-22 | Philips Image Guided Therapy Corporation | Deep vein thrombosis therapeutic methods |
WO2013033489A1 (en) | 2011-08-31 | 2013-03-07 | Volcano Corporation | Optical rotary joint and methods of use |
US9292918B2 (en) | 2012-10-05 | 2016-03-22 | Volcano Corporation | Methods and systems for transforming luminal images |
US10568586B2 (en) | 2012-10-05 | 2020-02-25 | Volcano Corporation | Systems for indicating parameters in an imaging data set and methods of use |
US9367965B2 (en) | 2012-10-05 | 2016-06-14 | Volcano Corporation | Systems and methods for generating images of tissue |
US10070827B2 (en) | 2012-10-05 | 2018-09-11 | Volcano Corporation | Automatic image playback |
US9286673B2 (en) | 2012-10-05 | 2016-03-15 | Volcano Corporation | Systems for correcting distortions in a medical image and methods of use thereof |
US9324141B2 (en) | 2012-10-05 | 2016-04-26 | Volcano Corporation | Removal of A-scan streaking artifact |
US9307926B2 (en) | 2012-10-05 | 2016-04-12 | Volcano Corporation | Automatic stent detection |
US9858668B2 (en) | 2012-10-05 | 2018-01-02 | Volcano Corporation | Guidewire artifact removal in images |
US11272845B2 (en) | 2012-10-05 | 2022-03-15 | Philips Image Guided Therapy Corporation | System and method for instant and automatic border detection |
JP2015532536A (ja) | 2012-10-05 | 2015-11-09 | デイビッド ウェルフォード, | 光を増幅するためのシステムおよび方法 |
US9840734B2 (en) | 2012-10-22 | 2017-12-12 | Raindance Technologies, Inc. | Methods for analyzing DNA |
EP2931132B1 (en) | 2012-12-13 | 2023-07-05 | Philips Image Guided Therapy Corporation | System for targeted cannulation |
EP2934311B1 (en) | 2012-12-20 | 2020-04-15 | Volcano Corporation | Smooth transition catheters |
US10942022B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Manual calibration of imaging system |
CA2895989A1 (en) | 2012-12-20 | 2014-07-10 | Nathaniel J. Kemp | Optical coherence tomography system that is reconfigurable between different imaging modes |
US10939826B2 (en) | 2012-12-20 | 2021-03-09 | Philips Image Guided Therapy Corporation | Aspirating and removing biological material |
US11406498B2 (en) | 2012-12-20 | 2022-08-09 | Philips Image Guided Therapy Corporation | Implant delivery system and implants |
EP2934282B1 (en) | 2012-12-20 | 2020-04-29 | Volcano Corporation | Locating intravascular images |
JP2016501623A (ja) | 2012-12-21 | 2016-01-21 | アンドリュー ハンコック, | 画像信号のマルチ経路処理のためのシステムおよび方法 |
US10058284B2 (en) | 2012-12-21 | 2018-08-28 | Volcano Corporation | Simultaneous imaging, monitoring, and therapy |
CA2895990A1 (en) | 2012-12-21 | 2014-06-26 | Jerome MAI | Ultrasound imaging with variable line density |
US9383263B2 (en) | 2012-12-21 | 2016-07-05 | Volcano Corporation | Systems and methods for narrowing a wavelength emission of light |
WO2014099763A1 (en) | 2012-12-21 | 2014-06-26 | Jason Spencer | System and method for graphical processing of medical data |
WO2014100162A1 (en) | 2012-12-21 | 2014-06-26 | Kemp Nathaniel J | Power-efficient optical buffering using optical switch |
EP2934653B1 (en) | 2012-12-21 | 2018-09-19 | Douglas Meyer | Rotational ultrasound imaging catheter with extended catheter body telescope |
US9612105B2 (en) | 2012-12-21 | 2017-04-04 | Volcano Corporation | Polarization sensitive optical coherence tomography system |
US9486143B2 (en) | 2012-12-21 | 2016-11-08 | Volcano Corporation | Intravascular forward imaging device |
US10413317B2 (en) | 2012-12-21 | 2019-09-17 | Volcano Corporation | System and method for catheter steering and operation |
US10226597B2 (en) | 2013-03-07 | 2019-03-12 | Volcano Corporation | Guidewire with centering mechanism |
US9770172B2 (en) | 2013-03-07 | 2017-09-26 | Volcano Corporation | Multimodal segmentation in intravascular images |
EP2967391A4 (en) | 2013-03-12 | 2016-11-02 | Donna Collins | SYSTEMS AND METHODS FOR DIAGNOSING CORONARY MICROVASCULAR DISEASE |
US20140276923A1 (en) | 2013-03-12 | 2014-09-18 | Volcano Corporation | Vibrating catheter and methods of use |
US9301687B2 (en) | 2013-03-13 | 2016-04-05 | Volcano Corporation | System and method for OCT depth calibration |
JP6339170B2 (ja) | 2013-03-13 | 2018-06-06 | ジンヒョン パーク | 回転式血管内超音波装置から画像を生成するためのシステム及び方法 |
US11026591B2 (en) | 2013-03-13 | 2021-06-08 | Philips Image Guided Therapy Corporation | Intravascular pressure sensor calibration |
US10426590B2 (en) | 2013-03-14 | 2019-10-01 | Volcano Corporation | Filters with echogenic characteristics |
US10292677B2 (en) | 2013-03-14 | 2019-05-21 | Volcano Corporation | Endoluminal filter having enhanced echogenic properties |
US10219887B2 (en) | 2013-03-14 | 2019-03-05 | Volcano Corporation | Filters with echogenic characteristics |
EP3212204B1 (en) * | 2014-10-28 | 2019-07-03 | Biovotec AS | Micronized eggshell membrane particles and the use thereof to promote the healing of wounds |
EP3313464B1 (en) | 2015-06-24 | 2020-08-26 | Biovotec AS | Tissue engineering scaffolds comprising particulate egg shell membrane |
WO2017007776A1 (en) * | 2015-07-06 | 2017-01-12 | Archangel, Llc | Method and system for treatment of microorganisms during propagation, conditioning, fermentation, and preservation using lae and selected additives |
GB201519923D0 (en) | 2015-11-11 | 2015-12-23 | Biovotec Dac And Biovotec As | Dry biocompatible disintegrateable films for delivering particulate egg shell membrane to a wound |
WO2018201119A1 (en) | 2017-04-29 | 2018-11-01 | Nevada Naturals Inc. | Biofilm penetrating compositions and methods |
US11840499B2 (en) * | 2020-02-28 | 2023-12-12 | The United States Of America, As Represented By The Secretary Of Agriculture | Biobased-fatty acid arginates |
KR102350121B1 (ko) * | 2020-08-10 | 2022-01-12 | 건국대학교 산학협력단 | 항생제 내성 황색포도상구균 억제용 항균 조성물 |
KR20240036492A (ko) | 2021-01-27 | 2024-03-20 | 펩토닉 메디컬 에이비 | 생물막 분해 또는 생물막 형성 방지에 사용하기 위한 조성물 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3069320A (en) * | 1958-11-18 | 1962-12-18 | American Cyanamid Co | Synergistic sanitizing process with neomycin and selected cationic surface active quaternary ammonium salts |
US3839297A (en) * | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
US4027676A (en) * | 1975-01-07 | 1977-06-07 | Ethicon, Inc. | Coated sutures |
JPS5283942A (en) * | 1976-01-01 | 1977-07-13 | Ajinomoto Co Inc | Medicine for superficial infection through skin |
US4201216A (en) * | 1976-12-15 | 1980-05-06 | Ethicon, Inc. | Absorbable coating composition for sutures |
US4185637A (en) * | 1978-05-30 | 1980-01-29 | Ethicon, Inc. | Coating composition for sutures |
JPS59212405A (ja) | 1983-05-18 | 1984-12-01 | Lion Corp | 防かび剤組成物 |
DK154806C (da) | 1986-12-19 | 1989-06-26 | Coloplast As | Saarplejemiddel indeholdende et aktivt stof til fremme af saarbehandlingen og fremgangsmaade til fremstilling deraf |
WO1992018098A1 (en) * | 1991-04-10 | 1992-10-29 | Capelli Christopher C | Antimicrobial compositions useful for medical applications |
WO1994019027A1 (en) | 1993-02-26 | 1994-09-01 | Wesley-Jessen Corporation | Method and composition for disinfecting contact lenses |
US5869073A (en) * | 1993-12-20 | 1999-02-09 | Biopolymerix, Inc | Antimicrobial liquid compositions and methods for using them |
JP3637617B2 (ja) * | 1994-12-28 | 2005-04-13 | 味の素株式会社 | 殺菌消毒用組成物 |
JPH10183705A (ja) | 1996-11-07 | 1998-07-14 | Noriatsu Kojima | 排水用集合管継手 |
AU5153399A (en) * | 1998-08-14 | 2000-03-06 | Coloplast A/S | Stabilised compositions having antibacterial activity |
KR100411178B1 (ko) | 2000-10-09 | 2003-12-18 | 한국화학연구원 | 신규 항균제와 이러한 항균제를 함유하는 항균탈취성 용액 |
US7758851B2 (en) | 2001-08-09 | 2010-07-20 | Laboratorios Miret, S.A. | Preservative systems and their use in cosmetic preparations |
US6767551B2 (en) * | 2001-08-15 | 2004-07-27 | Sherwood Services Ag | Coating for use with medical devices and method of making same |
EP2082724B1 (en) * | 2001-11-15 | 2013-08-21 | Laboratorios Miret, S.A. | Use of cationic surfactant as antimicrobial activity enhancer in deodorants and oral care |
US20050192547A1 (en) * | 2002-01-31 | 2005-09-01 | Modak Shanta M. | Combinations of antiseptic and antibiotic agents containing medical devices |
US20060177548A1 (en) | 2005-02-08 | 2006-08-10 | Unilever Bestfoods, North America | Preservative system |
US20060263444A1 (en) | 2005-05-19 | 2006-11-23 | Xintian Ming | Antimicrobial composition |
US20060264347A1 (en) | 2005-05-19 | 2006-11-23 | Xintian Ming | Antimicrobial composition |
AU2006294652A1 (en) * | 2005-09-28 | 2007-04-05 | University Of Massachusetts | Stabilized antimicrobial compositions and related methods of preparation |
-
2006
- 2006-03-27 US US11/389,824 patent/US8604073B2/en active Active
-
2007
- 2007-03-27 JP JP2009503207A patent/JP5254207B2/ja not_active Expired - Fee Related
- 2007-03-27 DE DE602007008696T patent/DE602007008696D1/de active Active
- 2007-03-27 WO PCT/US2007/064990 patent/WO2007112379A2/en active Application Filing
- 2007-03-27 ES ES07759438T patent/ES2349065T3/es active Active
- 2007-03-27 AT AT07759438T patent/ATE478558T1/de not_active IP Right Cessation
- 2007-03-27 EP EP07759438A patent/EP1998615B1/en not_active Not-in-force
- 2007-03-27 CN CN2007800191219A patent/CN101573031B/zh not_active Expired - Fee Related
- 2007-03-27 AU AU2007230597A patent/AU2007230597B2/en not_active Ceased
- 2007-03-27 CA CA2647642A patent/CA2647642C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101573031A (zh) | 2009-11-04 |
DE602007008696D1 (de) | 2010-10-07 |
EP1998615B1 (en) | 2010-08-25 |
ES2349065T3 (es) | 2010-12-22 |
US20070225220A1 (en) | 2007-09-27 |
WO2007112379A3 (en) | 2008-12-18 |
WO2007112379A2 (en) | 2007-10-04 |
CA2647642A1 (en) | 2007-10-04 |
ATE478558T1 (de) | 2010-09-15 |
AU2007230597B2 (en) | 2012-04-26 |
AU2007230597A1 (en) | 2007-10-04 |
US8604073B2 (en) | 2013-12-10 |
CA2647642C (en) | 2014-10-07 |
EP1998615A2 (en) | 2008-12-10 |
CN101573031B (zh) | 2013-11-20 |
JP2009531458A (ja) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5254207B2 (ja) | 抗菌性組成物 | |
EP1887871B1 (en) | Antimicrobial composition | |
US20190076581A1 (en) | Cationic steroidal antibiotic compositions for the treatment of dermal tissue | |
US20060264347A1 (en) | Antimicrobial composition | |
US9968710B2 (en) | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition | |
RU2628539C2 (ru) | Антимикробные составы широкого спектра действия на основе сочетания тауролидина и протамина, а также медицинские устройства, содержащие такие составы | |
US20110245148A1 (en) | Acetic acid and a buffer | |
Cashman et al. | The use of tissue sealants to deliver antibiotics to an orthopaedic surgical site with a titanium implant | |
US6395288B1 (en) | Subversion of bacterial resistance by low solubility antibiotics | |
EP2892342B1 (en) | An antibiofilm and methods for making and using the same | |
US20190015385A1 (en) | Vitamin e phosphate or acetate for use in the treatment and prevention of biofilm infections | |
Roberts | Antimicrobial agents used in wound care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100311 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100715 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20111205 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120828 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130417 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5254207 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |